Computational drug discovery under RNA times

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Drug Discovery

Background:

• Ribonucleic acid (RNA) molecules are increasingly recognized for their diverse functional and regulatory roles within cells.
• RNA-based therapeutics are gaining significant attention in modern medicine.
• Structure-based approaches have proven successful in identifying small-molecule drugs for protein targets.

Purpose of the Study:

• To discuss the challenges of applying traditional structure-based drug discovery methods to RNA targets.
• To explore the specific considerations for small-molecule recognition and binding to RNA.
• To address the critical aspects of selectivity and the anticipated properties of RNA-targeting ligands.

Main Methods:

• Computational chemistry perspectives on structure-based drug design.
• Analysis of molecular recognition principles between small molecules and RNA.
• Evaluation of selectivity challenges in RNA-targeted drug discovery.
• Prediction and characterization of potential RNA ligand properties.

Main Results:

• Extending structure-based approaches to RNA presents unique challenges compared to protein targets.
• Understanding RNA-small molecule interactions requires specialized considerations for RNA structure and dynamics.
• Achieving selectivity for specific RNA structures or sequences is a key hurdle.

Conclusions:

• Computational chemists face distinct challenges when adapting structure-based drug discovery for RNA targets.
• Further research is needed to refine methods for RNA-small molecule recognition, selectivity, and ligand design.
• Successful development of RNA-targeted therapeutics will rely on overcoming these computational and chemical hurdles.